How should we use the short acting insulin analog in external pumps?;Comment utiliser l'analogue de l'insuline lys-pro en perfusion sous-cutanée continue par pompe portable ?

Diabetes and Metabolism

Volumn 26, Issue 6, 2000, Pages 513-519

  Guerci, B ^a   Jeandidier, N ^a   Lassmann Vague, V ^a   Renard, E ^a   Hanaire Broutin, H ^a  

^a Ctr Hospitalier Univ de Nancy   (France)

Author keywords

Continuous subcutaneous insulin infusion; External pump; Insulin analogues; Type 1 diabetes mellitus

Indexed keywords

HUMAN INSULIN; INSULIN LISPRO; UMULINE RAPIDE; UNCLASSIFIED DRUG; VELOSULINE;

CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES CONTROL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; PATIENT MONITORING; POSTPRANDIAL STATE; REVIEW; SELF MONITORING; URINE LEVEL;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 0034492660     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Pros and cons of continuous subcutaneous insulin infusion
2. Post-prandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients
3. Continous subcutaneous insulin infusion (CSII), multiple injections (MI) and conventional insulin therapy (CT) in selfselecting insulin-dependent diabetic patients. A comparison of metabolic control, acute complications and patient preference
4. Variability of blood glucose levels in patients treated with continuous subcutaneous insulin infusion : A pilot study
5. Implementation of treatment protocols in the diabetes control and complications trial
6. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes
7. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus : A meta-analysis
8. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control
9. Insulin Lispro
10. Insulin Lispro in CSII. Results of a double-blind crossover study
11. Improvement of HbA1c and blood glucose stability in IDDM patients treated with Lispro insulin analog in external pumps
12. Use of insulin lispro in continuous subcutaneous insulin infusion treatment
13. The Study group for the development of pump therapy in diabetes. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. A randomized study
14. Human insulin analogue (Lys (B28), pro (B29)) : The ideal pump insulin ?
15. Stability of insulin Lispro in insulin infusion systems
16. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM
17. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with Lispro insulin
18. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients
19. Comparison of human regular and Lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM
20. Pompes à insuline (pompe portable à perfusion sous cutanée d'insuline)
21. Optimal time of administration of insulin Lispro
22. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM
23. Exercice-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue